




版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
PepticUlcerDisease(PUD)ZhongLiangHuaShanHospital1DefinitionAcircumscribedulcerationofthegastrointestinalmucosaoccurringinareasexposedtoacidandpepsinandmostoftencausedbyHelicobacterpyloriinfection.(Uphold&Graham,2003)2Pepticulcers:
GastricandDuodenal3PUDDemographicsHigherprevalenceindevelopingcountries
H.PyloriissometimesassociatedwithsocioeconomicstatusandpoorhygieneIntheUS:
Lifetimeprevalenceis~10%.PUDaffects~4.5millionannually.Hospitalizationrateis~30ptsper100,000cases.Mortalityratehasdecreaseddramaticallyinthepast20yearsapproximately1deathper100,000cases
4ComparingDuodenal
AndGastricUlcers5Epidemiology(DU)Duodenalsitesare4xascommonasgastricsitesMostcommoninmiddleagepeak30-50yearsMaletofemaleratio—4:1Geneticlink:3xmorecommonin1stdegreerelativesMorecommoninpatientswithbloodgroupOAssociatedwithincreasedserumpepsinogenH.pyloriinfectioncommonupto95%Smokingistwiceascommon6GastricUlcersCommoninlatemiddleageincidenceincreaseswithageMaletofemaleratio—2:1MorecommoninpatientswithbloodgroupAUseofNSAIDs-associatedwithathree-tofour-foldincreaseinriskofgastriculcerLessrelatedtoH.pylorithanduodenalulcers–about80%10-20%ofpatientswithagastriculcerhaveaconcomitantduodenalulcer7EtiologyApepticulcerisamucosalbreak,3mmorgreater,thatcaninvolvethestomachorduodenum.ThemostimportantcontributingfactorsareHpylori,NSAIDs,acid,andpepsin.Additionalaggressivefactorsincludesmoking,ethanol,bileacids,aspirin,steroids,andstress.Importantprotectivefactorsaremucus,bicarbonate,mucosalbloodflow,prostaglandins,hydrophobiclayer,andepithelialrenewal.Increasedriskwhenolderthan50d/tdecreaseprotectionWhenanimbalanceoccurs,PUDmightdevelop.89HelicobactorpyloriH.pylori→
?→ulcerationPrevalenceofH.pylori:80%indevelopingarea;20-50%indevelopedareaTherateofH.pyloriinfectionisdecliningindevelopedcountryTransmission:oral→oralfecal→oral10HelicobactorpyloriItispossiblethatthedifferentdiseaserelatedtoH.pyloriinfectioncanbeattributetodifferentstrainsoforganismwithdistinctpathogenicfeatures11Helicobactorpylori12Helicobactorpylori13NSAIDNSAID→COX→PG↓TheformofNSAIDshavenorelationtotheirdamageonGImucosa!!14NSAIDRiskfactor:AdvancedageHistoryofulcerConcomitantuseofglucocorticoidsConcomitantuseofanticogulantsSeriousormulti-systemdiseaseH.pyloriinfectionCigaretteand/oralcoholconsumption
15SubjectiveDataPain—”gnawing”,“aching”,or“burning”Duodenalulcers:occurs1-3hoursafteramealandmayawakenpatientfromsleep.Painisrelievedbyfood,antacids,orvomiting.Gastriculcers:foodmayexacerbatethepainwhilevomitingrelievesit.Nausea,vomiting,belching,dyspepsia,bloating,chestdiscomfort,anorexia,hematemesis,&/ormelenamayalsooccur.
nausea,vomiting,&weightlossmorecommonwithGastriculcers16ObjectiveDataEpigastrictendernessGuaic-positivestoolresultingfromoccultbloodlossSuccussionsplashresultingfromscaringoredemaduetopartialorcompletegastricoutletobstructionAsuccussionsplashdescribesthesoundobtainedbyshakinganindividualwhohasfreefluidandairorgasinaholloworganorbodycavity.Usuallyelicitedtoconfirmintestinalorpyloricobstruction.Donebygentlyshakingtheabdomenbyholdingeithersideofthepelvis.Apositivetestoccurswhenasplashingnoiseisheard,eitherwithorwithoutastethoscope.Itisnotvalidifthepthaseatenordrunkfluidwithinthelastthreehours.17ComplicationsPerforation&Penetration—intopancreas,liverandretroperitonealspacePeritonitisBowelobstruction,Gastricoutflowobstruction,&PyloricstenosisBleeding--occursin25%to33%ofcasesandaccountsfor25%ofulcerdeaths.GastricCA18Activebleeding19胃角潰瘍出血錄像.avi20GastricCA21Pepticulcer–specialSilentulcerPepticulcerinadvancedagePepticulceronposteriorbulbPepticulceronpylorustubeGiantpepticulcer22DiagnosticPlanStoolforfecaloccultbloodLabs:CBC(R/Obleeding),liverfunctiontest,amylase,andlipase.H.Pyloricanbediagnosedbyureabreathtest,bloodtest,stoolantigenassays,&rapidureasetestonabiopsysample.Bariummeal23DiagnosticPlanUpperGIEndoscopy:Anypt>50ywithnewonsetofsymptomsorthosewithalarmmarkingsincludinganemia,weightloss,orGIbleeding.Preferreddiagnostictestb/citshighlysensitivefordxofulcersandallowsforbiopsytoruleoutmalignancyandrapidureasetestsfortestingforH.Pylori.24Gastriculcer25Duodenalulcer26DifferentialDiagnosisNeoplasmofthestomachPancreatitisPancreaticcancerDiverticulitisNonulcerdyspepsia(alsocalledfunctionaldyspepsia)CholecystitisGastritisGERDMI—nottobemissedifhavingchestpain27Treatment--antacidMixtureofaluminumhydroxideandmagnesiumhydroxideTalcid
28Treatment—acidsecretioninhabitorProtonPumpInhibitorsPPI:Prilosec,Prevacid,Nexium,Protonix,orAciphexfor4-8weeksH2
receptorantagonistsHRA:Tagament,Pepcid,Axid,orZantacforupto8weeks29不同抑酸劑的作用機(jī)理丙谷胺雷尼替丁哌侖西平GH2MPPhe+H+K+壁細(xì)胞PPI
H+30Treatment–H.pylorieradicationTripletherapyfor14daysisconsideredthetreatmentofchoice.
ProtonPumpInhibitor+clarithromycinandamoxicillinOmeprazole(Prilosec):20mgPObidfor14dor
Lansoprazole(Prevacid):30mgPObidfor14dor
Rabeprazole(Aciphex):20mgPObidfor14dor
Esomeprazole(Nexium):40mgPOqdfor14dplus
Clarithromycin(Biaxin):500mgPObidfor14and
Amoxicillin(Amoxil):1gPObidfor14dCansubstituteFlagyl500mgPObidfor14difallergictoPCNInthesettingofanactiveulcer,continueqdprotonpumpinhibitortherapyforadditional2weeks.31Treatment–H.pylorieradicationQuadrupletherapyfortheinfectionofresistantorganism
Omeprazole20mgqdBismuthsubsalicylate2tabletsqidMetronidazole250mgqidTetracycline500mgqidGoal:completeeliminationofH.Pylori.Onceachievedre-infectionratesarelow.Compliance!32Treatment—NSAIDrelatedPUDPrevention!H2RAPPIMisoprostolSelectiveCOX-2inhibitorsH.pylorieradication33Treatment–cytoprotectiveagentsSucralfateBismuth-ContainingPreparationsProstaglandinAnalogues34GUactivetohealed35DUactivetohealed36LifestyleChangesDiscontinueNSAIDsanduseAcetaminophenforpaincontrolifpossible.Acidsuppression--AntacidsSmokingcessationNodietaryrestrictionsunlesscertainfoodsareassociatedwithproblems.AlcoholinmoderationMenunder65:2drinks/dayMenover65andallwomen:1drink/dayStressreduction37PreventionConsiderprophylactictherapyforthefollowingpatients:PtswithNSAID-inducedulcerswhorequiredailyNSAIDtherapyPtsolderthan60yearsPtswithahistoryofPUDoracomplicationsuchasGIbleedingPtstakingsteroidsoranticoagulantsorpatientswithsignificantcomorbidmedicalillnessesProphylacticregimensthathavebeenshowntodramaticallyreducetheriskofNSAID-inducedgastricandduodenalulcersincludetheuseofaprostaglandinanalogueoraprotonpumpinhibitor.Misoprostol(Cytotec)100-200mcgPO4timesperdayOmeprazole(Prilosec)20-40mgPOeverydayLansoprazole(Prevacid)15-30mgPOeveryday38SurgeryPeoplewhodonotrespondtomedication,orwhodevelopcomplications:Vagotomy-cuttingthevagusnervetointerruptmessagessentfromthebraintot
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- DB31/T 522-2023通風(fēng)機(jī)系統(tǒng)節(jié)能改造技術(shù)規(guī)范
- DB31/T 392-2018工業(yè)旅游景點(diǎn)服務(wù)質(zhì)量要求
- DB31/T 1212-2020冷水機(jī)組節(jié)能現(xiàn)場(chǎng)檢測(cè)技術(shù)要求
- DB31/T 1208-2020濕垃圾處理殘余物的生物穩(wěn)定性評(píng)價(jià)方法
- DB31/T 1160-2019畜禽養(yǎng)殖過(guò)程細(xì)菌耐藥性監(jiān)測(cè)技術(shù)規(guī)范
- DB31/T 1111-2018采摘體驗(yàn)基地旅游服務(wù)規(guī)范
- DB31/T 1044-2017軍隊(duì)離休退休干部服務(wù)管理機(jī)構(gòu)服務(wù)規(guī)范
- DB31/ 17-2012資源綜合利用發(fā)電運(yùn)行管理規(guī)范
- CAB 1023-2014便攜式節(jié)水洗車器
- 2025設(shè)備采購(gòu)合同書(shū)協(xié)議范本
- 電子工程師考試試題
- 公益慈善基金會(huì)的品牌建設(shè)與傳播
- 《胖東來(lái)企業(yè)文化指導(dǎo)手冊(cè)》
- 浙江省寧波市鄞州區(qū)2023-2024學(xué)年八年級(jí)下學(xué)期期末數(shù)學(xué)試題
- 新行政訴訟法課件講座
- 2024年湖南湘西自治州公開(kāi)招募“三支一扶”高校畢業(yè)生(高頻重點(diǎn)復(fù)習(xí)提升訓(xùn)練)共500題附帶答案詳解
- 打地坪施工合同范本
- 廠區(qū)保潔服務(wù)投標(biāo)方案【2024版】技術(shù)方案
- 2024中考化學(xué)成都10年考情及趨勢(shì)分析【必考知識(shí)點(diǎn)】
- 腹腔鏡手術(shù)設(shè)備使用說(shuō)明與注意事項(xiàng)
- 二手房委托代理協(xié)議書(shū)范本參考
評(píng)論
0/150
提交評(píng)論